Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
July 07, 2021 12:51 ET
|
Ischemix, Inc.
GRAFTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, today announced that the US Department of...
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 23, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
Programme aims to support students from under-represented ethnic groups London, UK – 23 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Sensory Challenges and Anxiety in Children with and without Autism - A Free Webinar from the Brain & Behavior Research Foundation
March 02, 2021 09:00 ET
|
Brain & Behavior Research Foundation
New York, March 02, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Sensory Challenges and Anxiety in Children with and without Autism” on...
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
February 16, 2021 13:23 ET
|
Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...
Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System
February 03, 2021 15:34 ET
|
Spark Biomedical
Danville, KY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Dr. Anjum Bux, a leading expert in pain management, was the first in the nation to successfully treat commercial patients using Transcutaneous...
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
February 01, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
January 29, 2021 12:05 ET
|
Novartis International AG
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on...
German University Hospital Orders Nexstim NBS System with NexSpeech
January 28, 2021 04:40 ET
|
Nexstim Oyj
Press release, Helsinki, 28 January 2021 at 11.40 am (EET) German University Hospital Orders Nexstim NBS System with NexSpeech Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults
January 04, 2021 16:38 ET
|
Spark Biomedical
Dallas, TX, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to The Sparrow Therapy System, a...